Genzyme and Relational Investors: Science and Business Collide Harvard Case Solution & Analysis

Chairman and Chief Executive Officer of Genzyme, one the country's top five biotechnology companies, received a phone call requesting a meeting with the co-founder and director of a large hedge fund, which now has a 2.6% stake in the company. Before I met him, CEO realizes that he needs a strategy for dealing with this "activist" investor with a track record of displacement leaders. "Hide
by Kenneth Eades, Pedro Matos, Rick Green Source: Darden School of Business 25 pages. Publication Date: December 2, 2011. Prod. #: UV6529-PDF-ENG

Share This

SALE SALE

Save Up To

30%

IN ONLINE CASE STUDY

FOR FREE CASES AND PROJECTS INCLUDING EXCITING DEALS PLEASE REGISTER YOURSELF !!

Register now and save up to 30%.